SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

This publication has 77 references indexed in Scilit:

• Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
  Journal of Bone and Mineral Research, 2012
• Visualization of Src and FAK Activity during the Differentiation Process from HMSCs to Osteoblasts
  PLOS ONE, 2012
• Current Status of Src Inhibitors in Solid Tumor Malignancies
  The Oncologist, 2011
• Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
  Oncogene, 2010
• Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals
  Cancer Cell, 2009
• The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts
  Molecular Cancer Research, 2009
• Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice
  Journal of Clinical Investigation, 2008
• Effect of pathologic fractures on survival in multiple myeloma patients: a case control study
  Journal of Experimental & Clinical Cancer Research, 2008
• Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
  Blood, 2008
• Induction of mouse c-src in RAW264 cells is dependent on AP-1 and NF-κB and important for progression to multinucleated cell formation
  Biochemical and Biophysical Research Communications, 2004